## **Biosketch**

## ROBIN ROBINSON, Ph.D.

Dr. Robin Robinson currently serves as Vice President of Scientific Affairs for RenovaCare, Inc. directing development of cellular therapies for wound healing. Concurrently he is a Fellow for Regenerative Medicine and Biomedical Research at the Thought Leadership and Innovation (TLI) Foundation on regenerative medicines and independent consultant on vaccines and biodefense matters.

He reentered the biopharmaceutical business sector after retiring in 2016 from federal public service at the U.S. Department of Health and Human Services, where he served from 2008 - 2016 as the first director of the Biomedical Advanced Research and Development Authority (BARDA) and Deputy Assistant Secretary for Preparedness and Response and as BARDA's Influenza and Emerging Disease program director (2004-2008). Dr. Robinson brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of drugs, vaccines, diagnostics, and medical devices to address the deleterious outcomes of man-made biodefense threats, pandemic influenza, and emerging infectious diseases including Ebola and Zika viruses. 32 of its 250+ medical countermeasure products that BARDA supported since 2008 were fully approved and licensed by the FDA during his tenure; today that total is 52. Dr. Robinson established a pandemic influenza program with scientific and technical experts to implement the national and global strategic plans and policies for the development of new influenza antiviral drugs, vaccines, and diagnostics outlined in the National Strategy for Pandemic Influenza. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense's Clay Dalrymple Award in 2008, the HHS Distinguished Service Award three times, and a finalist for the Service to America Medal in 2009. In 2013-2015 Dr. Robinson was recognized as one of the top 50 most influential persons worldwide in vaccines by Vaccine Nation. In 2018 Dr. Robinson was recognized by Medicine Maker as one of the top 100 innovators in medicine.

Dr. Robinson received a Bachelor of Sciences degree in Biology from Millsaps College in 1976, a Doctoral degree in 1981 from the University of Mississippi Medical School in medical microbiology under Dr. Dennis O'Callaghan on herpesvirus oncogenesis, and completed in 1983 a NIH postdoctoral fellowship at the State University of New York at Stony Brook under Dr. Arnold Levine on molecular mechanisms in oncology. Dr. Robinson pursued his own research as a faculty member in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School from 1983-1992 on the molecular pathogenesis of herpesviruses and HIV. Prior to federal public service, Dr. Robinson served as the Director of Vaccines at Novavax, Inc. (Rockville, MD) from 1995-2004, where he led the development of 20+ vaccines to hepatitis B and E, influenza, HIV, noroviruses, and human papilloma viruses from early development, clinical trials, manufacturing scale-up, and commercialization through FDA licensure. While at Novavax, he developed patented platform vaccine technologies including virus-like particles and subunit protein vaccines for human pathogens including malaria, human papilloma, hepatitis, and influenza and for prostate, melanoma, and cervical cancers.

Dr. Robinson also served on the Senior Advisory Group for the World Health Organization (WHO) on emerging infectious diseases and pandemic influenza. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.